All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On 24 April, Paul Hampel from Mayo Clinic, Rochester, MN, USA, and colleagues, published in Leukemia & Lymphoma a systematic outcome evaluation following ibrutinib discontinuation in patients with chronic lymphocytic leukemia (CLL), outside the clinical trial setting.
Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor that has been approved by Food and Drug Administration (FDA) for the treatment of both relapsed/refractory and naïve CLL. Ibrutinib has shown great efficacy in CLL. Nevertheless, the clinical management and outcomes of patients who discontinue ibrutinib requires further investigation. Thus, the authors sought to identify the main reasons for ibrutinib discontinuation and the subsequent patient outcomes in patients with CLL, who received treatment in a real-world setting.
Toxicity |
56% (n = 29) |
---|---|
CLL progression |
17% (n = 9) |
Richter’s transformation (RT) |
15% (n = 8) |
Second malignancy: Lung adenocarcinoma Invasive non-melanoma skin cancer Merkel cell carcinoma |
6% (n = 3) n = 1 n = 1 n = 1 |
Other: Financial issues Patient choice |
6% (n = 3) n = 2 n = 1 |
Infection |
n = 6 |
---|---|
Bleeding |
n = 4 |
Arrhythmia |
n = 3 |
Gastrointestinal symptoms |
n = 3 |
Neutropenia |
n = 3 |
Median overall survival (OS) |
Months |
P value |
---|---|---|
In patients who stopped due to toxicity |
27.8 months |
0.04 |
In patients who stopped due to CLL or RT progression |
11.5 months |
The results of this real-world patient outcome analysis indicate that approximately one third of patients with CLL will discontinue ibrutinib treatment after two years. The most common reason for ibrutinib discontinuation was toxicity. Moreover, roughly 25% of the patients discontinuing ibrutinib progressed rapidly, further highlighting the medical need for such patient populations.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox